Descovy for PrEP

emtricitabine/tenofovir alafenamide (FTC/TAF)

FDA approved for the prevention of HIV
PrEP Drug Class Icon
Pre-Exposure Prophylaxis

Standard Dose

For HIV-negative adults and adolescents weighing at least 77 pounds (35 kg), one tablet once daily, without regard to food, for the prevention of HIV. At this time, Descovy for PrEP is not FDA approved for individuals vulnerable to HIV through receptive vaginal sex. The tablet contains 200 mg emtricitabine and 25 mg tenofovir alafenamide.

Take a missed dose as soon as possible, unless it is closer to the time of your next dose. Do not double up on your next dose. Descovy for PrEP is not recommended if CrCl is between 15 to less than 30 mL/min or under 15 if you are not on dialysis.

See Emtriva, which is contained in Descovy.

See package insert for more complete information on potential side effects and interactions.


Gilead Sciences, Inc.
(800) GILEAD-5 (445-3235)



Potential Side Effects and Toxicity

Potential Drug Interactions

More Information

Doctor Comments

Activist Comments